Morpholino-mediated splice switching of NELFE suppresses hepatocellular carcinoma cell phenotypes
Publication/Presentation Date
12-8-2026
Abstract
Hepatocellular carcinoma (HCC) is among the deadliest cancers worldwide, with rising incidence and few targeted therapies, driving high rates of recurrence and poor survival. Negative elongation factor E (NELFE), an RNA-binding subunit of the NELF complex, acts oncogenically when overexpressed and is associated with worse prognosis in HCC, yet no therapies target it. Here, we identify a rare germline intronic variant in the
Volume
37
Issue
4
First Page
103124
Last Page
103124
ISSN
2162-2531
Published In/Presented At
Reynolds, L. M., Lamm, R., Zhang, K., Barry-Wolbers, A. E., Lucci, A., Ruiz, B. N., Wessner, C. E., Nguyen, T., Hammond, K. M., Eckert, C., Liu, J. B., Choochuen, P., Hong, K. Y., Jiang, W., Forgues, M., Palazzo, G. M., Lin, D., Bodzin, A. S., Shah, A. P., Wang, X. W., … Dang, H. (2026). Morpholino-mediated splice switching of NELFE suppresses hepatocellular carcinoma cell phenotypes in vitro and in vivo. Molecular therapy. Nucleic acids, 37(4), 103124. https://doi.org/10.1016/j.omtn.2026.103124
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
42927183
Department(s)
Administration and Leadership
Document Type
Article